View Older Stories View More Recent Stories
-
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
-
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
-
Phio Pharmaceuticals Corp. (PHIO) Files for 5.93M Share Offering by Selling Stockholders
-
Phio Pharmaceuticals Announces Closing of $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
-
Phio Pharmaceuticals Corp. (PHIO) Prices 833.3K Share Offering at $3/sh
-
Phio Pharmaceuticals Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
-
Phio Pharmaceuticals Corp. (PHIO) Announces 1.06M Share Offering at $3/sh
-
Phio Pharmaceuticals Announces $3.19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
-
Phio Pharmaceuticals Corp. (PHIO) Reports Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762
-
Phio Pharmaceuticals Announces Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762
-
Phio Pharmaceuticals Corp. (PHIO) Announces Publication in Clinical, Cosmetic and Investigational Dermatology
-
Phio Pharmaceuticals Announces Publication in Clinical, Cosmetic and Investigational Dermatology
-
Phio Pharmaceuticals Corp. (PHIO) Prices 240K Share Offering at $2/sh
-
Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
-
Phio Pharmaceuticals Corp. (PHIO) Announces $1.15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
-
Phio Pharmaceuticals Announces $1.15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
-
Phio Pharmaceuticals Corp. (PHIO) Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762
-
Phio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762
-
Phio Pharmaceuticals Announces Publication in Frontiers in Immunology
-
Phio Pharmaceuticals is a Finalist for the Technology Disruptor of the Year Award
-
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
-
Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study
-
Phio Pharmaceuticals Corp. (PHIO) Tops Q3 EPS by 260c
-
Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
-
Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
-
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
-
Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
-
Correction to Registration Link to Access Phio Pharmaceuticals' Presentation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
-
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-deal Roadshow Series
-
Phio Pharmaceuticals (PHIO) Presenting Data on PH-894
-
Phio Pharmaceuticals Presenting Data on Its INSTAYL Compound PH-894 at ASGCT's 2024 Advancing Gene and Cell Therapies for Cancer Conference
-
Phio Announces Data Showcasing INTASYL's Role in Helping Immune Cells Target and Kill Cancer Cells
-
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
-
Phio Pharmaceuticals Announces Upcoming Presentation at ASGCT's 2024 Advancing Gene + Cell Therapies for Cancer Conference
-
INTASYL Technology and Compounds to be Focus of Presentation at 20th Annual Meeting of Oligonucleotide Therapeutics Society
-
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
-
Phio Pharmaceuticals Announces Presentation at the 9th Annual CAR-TCR Summit in Boston, MA
-
Phio Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
-
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
-
Phio Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
-
Phio Pharmaceuticals Announces Exploratory Collaboration with a Luxury Skin Care Company for Phio's Patented INTASYL Compound
-
Phio Pharmaceuticals (PHIO) Appoints Robert M. Infarinato as CFO
-
Phio Pharmaceuticals Announces New Chief Financial Officer
-
Phio Pharmaceuticals (PHIO) to Receive $3.1M Gross Proceeds from Warrant Exercise
-
Phio Pharmaceuticals Announces Exercise of Warrants for $3.1 Million Gross Proceeds
-
Phio Pharmaceuticals (PHIO) Announces Addition of Clinical Trial Site for its Phase 1b study of PH-762
-
Phio Pharmaceuticals Announces Addition of Clinical Trial Site for its Phase 1b study of PH-762
-
Phio Pharmaceuticals Corp. (PHIO) Terminates Share Purchase Agreement with Triton Funds
-
Phio Pharmaceuticals Terminates Share Purchase Agreement with Triton Funds
-
Phio Pharmaceuticals Corp. (PHIO) Announces Reverse Stock Split
